By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Gilead Sciences, Inc. 

333 Lakeside Drive

Foster City  California  94404  U.S.A.
Phone: 800-GILEAD-5 or 650-574-3000 Fax: 650-522-5800


Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need.The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.

Key Statistics

Ownership: Public

Web Site: Gilead
Employees: 4,000
Symbol: GILD


Company News
European CHMP Adopts Positive Opinion On Gilead (GILD)’s Type II Variation Application For Truvada For Reducing The Risk Of Sexually Acquired HIV 7/22/2016 9:01:20 AM
Gilead (GILD)'s Odefsey Successful in Two Phase IIIb Studies 7/22/2016 6:29:41 AM
A Look at Who Could Buy Gilead (GILD) and Who Gilead Should Buy 7/21/2016 6:58:30 AM
Gilead (GILD) To Release Second Quarter 2016 Financial Results On Monday, July 25, 2016 7/19/2016 11:09:49 AM
Evaluation: 7 Biopharma Companies’ Market Value Based on Pipelines 7/14/2016 6:31:45 AM
Gilead (GILD) Receives Approval In Canada For EPCLUSA (Sofosbuvir/Velpatasvir), The First Once-Daily Pan-Genotypic (Genotypes 1-6) Single Tablet Regimen For The Treatment Of Chronic Hepatitis C 7/14/2016 6:10:18 AM
Gilead (GILD) Used Legal Loopholes to Avoid Paying $10 Billion in Taxes Last Year 7/13/2016 3:27:59 PM
Good News for Gilead (GILD) as Zydelig Passes Safety Review Test Despite Trial Deaths 7/12/2016 7:36:33 AM
European Commission (EC) Grants Marketing Authorization For Gilead (GILD)’s Epclusa (Sofosbuvir/Velpatasvir) For The Treatment Of All Genotypes Of Chronic Hepatitis C 7/8/2016 10:40:51 AM
Ligand (LGND) Enters Into Omniab Platform License Agreement With Gilead (GILD) 7/8/2016 8:14:21 AM